Markets:

Overview

News

Currencies

International

Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

8.515 -0.075 (-0.87%)

Streaming Delayed Price Updated: 11:41 AM EDT, Jul 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results

July 25, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases

June 08, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference

June 01, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

Expert Ratings For Ocular Therapeutix ↗

November 09, 2021

Ocular Therapeutix (NASDAQ:OCUL) has observed the following analyst rating...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

May 27, 2022

During Friday's session, 59 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

May 26, 2022

On Thursday, 94 companies set new 52-week lows.

Via Benzinga

Expert Ratings for Ocular Therapeutix ↗

May 10, 2022

Over the past 3 months, 4 analysts have published their opinion on Ocular Therapeutix (NASDAQ:OCUL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding...

Via Benzinga

Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update

May 09, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting

May 03, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Earnings Scheduled For May 9, 2022 ↗

May 09, 2022

Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.

Via Benzinga

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

April 29, 2022

Gainers Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million.

Via Benzinga

Ocular Therapeutix™ to Report First Quarter 2022 Financial Results

April 26, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

April 25, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More ↗

April 17, 2022

Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting...

Via Benzinga

Ocular Therapeutix™ to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

April 14, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Thursday ↗

April 21, 2022

On Thursday, 236 companies hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

April 20, 2022

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...

Via Benzinga

Recap: Ocular Therapeutix Q4 Earnings ↗

February 28, 2022

Ocular Therapeutix (NASDAQ:OCUL) reported its Q4 earnings results on Monday, February 28, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results

February 22, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360

February 11, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

February 18, 2022

On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...

Via Benzinga

AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients

January 18, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

January 04, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix's Dexamethasone Ophthalmic Insert Meets Primary Goal In Dry Eye Disease Trial ↗

December 06, 2021

Ocular Therapeutix Inc (NASDAQ: OCUL) announced topline results from its Phase 2 trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-...

Via Benzinga

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease

December 06, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences

November 15, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix Stock Gains As Court Invalidates Drug Delivery Patent From Mati ↗

November 09, 2021

Ocular Therapeutix Inc (NASDAQ:OCUL) announce...

Via Benzinga

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

All News about Ocular Therapeutix, Inc. - Common Stock

Starting at /week.